Titan Pharmaceuticals, Inc. (TTNP)

Titan Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.18	0.56	1.53	4.84
Revenue Growth (YoY)	-	-66.97%	-63.50%	-68.46%	85.72%
Cost of Revenue	-	1.91	4.76	5.89	6.39
Gross Profit	-	-1.73	-4.2	-4.37	-1.55
Selling, General & Admin	4.56	5.55	6.03	4.99	5.8
Operating Expenses	4.56	5.55	6.03	4.99	5.8
Operating Income	-4.56	-7.28	-10.24	-9.35	-7.35
Interest Expense	-	-	-	-	-0.77
Interest & Investment Income	0	0.01	0.05	0	-
Other Non Operating Income (Expenses)	-0.15	-0.05	-0.02	-0.08	0.79
EBT Excluding Unusual Items	-4.71	-7.32	-10.21	-9.44	-7.33
Gain (Loss) on Sale of Assets	-	1.76	-	-	-
Other Unusual Items	-	-	-	0.66	-0.08
Pretax Income	-4.71	-5.57	-10.21	-8.78	-7.41
Earnings From Continuing Operations	-4.71	-5.57	-10.21	-8.78	-7.41
Earnings From Discontinued Operations	-	-	-	-	-10.84
Net Income	-4.71	-5.57	-10.21	-8.78	-18.24
Net Income to Common	-4.71	-5.57	-10.21	-8.78	-18.24
Shares Outstanding (Basic)	1	1	1	0	0
Shares Outstanding (Diluted)	1	1	1	0	0
Shares Change (YoY)	19.55%	11.91%	38.13%	157.89%	392.56%
EPS (Basic)	-5.23	-7.41	-15.19	-18.04	-96.70
EPS (Diluted)	-5.23	-7.41	-15.19	-18.04	-96.70
Free Cash Flow	-3.88	-7.09	-8.18	-7.92	-17.74
Free Cash Flow Per Share	-4.32	-9.43	-12.18	-16.28	-94.05
Gross Margin	-	-	-	-286.04%	-32.04%
Operating Margin	-	-3954.89%	-1837.52%	-612.97%	-151.94%
Profit Margin	-	-3026.63%	-1832.32%	-575.10%	-377.06%
Free Cash Flow Margin	-	-3855.43%	-1469.12%	-519.13%	-366.74%
EBITDA	-4.55	-7.17	-10.04	-9.13	-7.06
EBITDA Margin	-	-	-	-	-145.91%
D&A For EBITDA	0.01	0.11	0.2	0.22	0.29
EBIT	-4.56	-7.28	-10.24	-9.35	-7.35
EBIT Margin	-	-	-	-	-151.94%
Revenue as Reported	-	0.18	0.56	1.53	4.84

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q